POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (4.18.2021, 2:35pm CEST, WHO):   U.S. 73,697    India 261,500    Brazil 85,774    France 34,218    Russia 8,632    The United Kingdom 2,206    Turkey 62,606    Italy 15,364    Germany 19,185    Poland 12,151    Argentina 29,472    Columbia 16,703    Mexico 4,504    Iran 21,321    Ukraine 10,282    Peru 7,988    Indonesia 5,041    South Africa 1,325    The Netherlands 8,336    Chile 8,037    Canada 9,346    Romania 3,474    Iraq 6,552    Philippines 11,081    Hungary 3,706    Pakistan 4,976    Bangladesh 3,473    Jordan 1,596    Serbia 2,583    Austria 2,591    Japan 4,611    Lebanon 1,695    United Arab Emirates 1,958    Bulgaria 1,076    Malaysia 2,331    Ecuador 2,193    Belarus 1,384    Greece 2,411    Palestine 1,618    Croatia 1,565    Azerbaijan 2,148    Bolivia 1,246    Tunisia 2,199    Kuwait 1,388    Paraguay 2,278    Ethiopia 3,682    Costa Rica 1,044    Guatemala 1,640    Venezuela 1,244    Bahrain 1,024    Uruguay 3,070    Kenya 2,068    Puerto Rico 1,635    Cuba 1,026    Thailand 1,767    China 36    Singapore 39    New Zealand 5    Australia 21    South Korea 672   

FDA issues emergency use authorization for first U.S. coronavirus vaccine

Christian Fernsby |
The U.S. Food and Drug Administration (FDA) Friday issued authorization for emergency use of the first coronavirus vaccine in the United States.

Article continues below



Topics: U.S.   

The first Emergency Use Authorization (EUA) was issued to the coronavirus vaccine of American drugmaker Pfizer in partnership with German company BioNTech, allowing the vaccine to be distributed in the United States.

The FDA has determined that Pfizer-BioNTech coronavirus vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech coronavirus vaccine may be effective in preventing coronavirus, said the FDA in a statement.

The data also show that the known and potential benefits outweigh the known and potential risks, supporting the vaccine's use in millions of people 16 years of age and older, said the FDA.

"The FDA's authorization for emergency use of the first coronavirus vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world," said FDA Commissioner Stephen Hahn.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," he said in a statement.

The Pfizer-BioNTech vaccine contains a small piece of the SARS-CoV-2 virus's mRNA that instructs cells in the body to make the virus's distinctive "spike" protein.

When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

The vaccine is administered as a series of two doses, three weeks apart.

Global coronavirus cases surpassed 70 million on Friday, according to the Center for Systems Science and Engineering at Johns Hopkins University. The United States reported the most cases and deaths around the world as of 4:28 p.m. local time (2128 GMT), numbering 15,758,661 and 293,785, respectively.


What to read next

Dramatic increase in e-cigarette use among youth in U.S.
FDA's Marks: It deeply concerns us when we see preventable diseases reemerging
FDA Commissioner Scott Gottlieb on launch of The Real Cost youth e-cigarette prevention campaign